These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36777740)

  • 21. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.
    Pochtovyi AA; Kustova DD; Siniavin AE; Dolzhikova IV; Shidlovskaya EV; Shpakova OG; Vasilchenko LA; Glavatskaya AA; Kuznetsova NA; Iliukhina AA; Shelkov AY; Grinkevich OM; Komarov AG; Logunov DY; Gushchin VA; Gintsburg AL
    Vaccines (Basel); 2023 Sep; 11(10):. PubMed ID: 37896937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Markov State Models and Perturbation-Based Approaches Reveal Distinct Dynamic Signatures and Hidden Allosteric Pockets in the Emerging SARS-Cov-2 Spike Omicron Variants Complexes with the Host Receptor: The Interplay of Dynamics and Convergent Evolution Modulates Allostery and Functional Mechanisms.
    Xiao S; Alshahrani M; Gupta G; Tao P; Verkhivker G
    bioRxiv; 2023 May; ():. PubMed ID: 37292827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England.
    Kirsebom FCM; Harman K; Lunt RJ; Andrews N; Groves N; Abdul Aziz N; Hope R; Stowe J; Chand M; Ramsay M; Dabrera G; Kall M; Bernal JL
    Lancet Reg Health Eur; 2023 Dec; 35():100755. PubMed ID: 38115965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omicron BA.2.75 Subvariant of SARS-CoV-2 Is Expected to Have the Greatest Infectivity Compared with the Competing BA.2 and BA.5, Due to Most Negative Gibbs Energy of Binding.
    Popovic M
    BioTech (Basel); 2022 Oct; 11(4):. PubMed ID: 36278557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters.
    Mohandas S; Shete A; Kumar A; Wakchaure K; Rai V; Mote C; Dighe H; Sarkale P; Gawande P; Yemul J; Suryawanshi A; Joshi Y; Yadav PD
    Front Microbiol; 2023; 14():1183763. PubMed ID: 37426033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Markov State Models and Perturbation-Based Approaches Reveal Distinct Dynamic Signatures and Hidden Allosteric Pockets in the Emerging SARS-Cov-2 Spike Omicron Variant Complexes with the Host Receptor: The Interplay of Dynamics and Convergent Evolution Modulates Allostery and Functional Mechanisms.
    Xiao S; Alshahrani M; Gupta G; Tao P; Verkhivker G
    J Chem Inf Model; 2023 Aug; 63(16):5272-5296. PubMed ID: 37549201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effective Inhibitory Concentration of Interferon-β Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants.
    Singh J; Anantharaj A; Kumar P; Pandey R; Pandey AK; Medigeshi GR
    J Interferon Cytokine Res; 2024 Jul; 44(7):325-333. PubMed ID: 38557204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant.
    Scarpa F; Azzena I; Ciccozzi A; Giovanetti M; Locci C; Casu M; Fiori PL; Borsetti A; Cella E; Quaranta M; Pascarella S; Sanna D; Ciccozzi M
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 strain wars continues: Chemical and thermodynamic characterization of live matter and biosynthesis of Omicron BN.1, CH.1.1 and XBC variants.
    Popovic M
    Microb Risk Anal; 2023 Aug; 24():100260. PubMed ID: 36974134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A New-fangled COVID-19 Variant, Eris, Might be the One to Lookout in 2023 or far from Over.
    Ray SK; Mukherjee S
    Infect Disord Drug Targets; 2024; 24(6):e220124225916. PubMed ID: 38258765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deep mutational scans of XBB.1.5 and BQ.1.1 reveal ongoing epistatic drift during SARS-CoV-2 evolution.
    Taylor AL; Starr TN
    bioRxiv; 2023 Sep; ():. PubMed ID: 37745441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.
    Bruel T; Vrignaud LL; Porrot F; Staropoli I; Planas D; Guivel-Benhassine F; Puech J; Prot M; Munier S; Henry-Bolland W; Soulié C; Zafilaza K; Lusivika-Nzinga C; Meledge ML; Dorival C; Molino D; Péré H; Yordanov Y; Simon-Lorière E; Veyer D; Carrat F; Schwartz O; Marcelin AG; Martin-Blondel G;
    medRxiv; 2023 May; ():. PubMed ID: 37398037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant.
    Tamura T; Irie T; Deguchi S; Yajima H; Tsuda M; Nasser H; Mizuma K; Plianchaisuk A; Suzuki S; Uriu K; Begum MM; Shimizu R; Jonathan M; Suzuki R; Kondo T; Ito H; Kamiyama A; Yoshimatsu K; Shofa M; Hashimoto R; Anraku Y; Kimura KT; Kita S; Sasaki J; Sasaki-Tabata K; Maenaka K; Nao N; Wang L; Oda Y; ; Ikeda T; Saito A; Matsuno K; Ito J; Tanaka S; Sato K; Hashiguchi T; Takayama K; Fukuhara T
    Nat Commun; 2024 Feb; 15(1):1176. PubMed ID: 38332154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India - a cohort study.
    Selvavinayagam ST; Karishma SJ; Hemashree K; Yong YK; Suvaithenamudhan S; Rajeshkumar M; Aswathy B; Kalaivani V; Priyanka J; Kumaresan A; Kannan M; Gopalan N; Chandramathi S; Vignesh R; Murugesan A; Anshad AR; Ganesh B; Joseph N; Babu H; Govindaraj S; Larsson M; Kandasamy SL; Palani S; Singh K; Byrareddy SN; Velu V; Shankar EM; Raju S
    Lancet Reg Health Southeast Asia; 2023 Dec; 19():100272. PubMed ID: 38076717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Further quantitative in silico analysis of SARS-CoV-2 S-RBD Omicron BA.4, BA.5, BA.2.75, BQ.1, and BQ.1.1 transmissibility.
    Hanai T
    Talanta; 2023 Mar; 254():124127. PubMed ID: 36462284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?
    Ngiam JN; Al-Mubaarak A; Maurer-Stroh S; Tambyah PA
    Singapore Med J; 2022 Dec; ():. PubMed ID: 36648003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity.
    DeGrasse DC; Black SD
    Cureus; 2023 Jun; 15(6):e40148. PubMed ID: 37313287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strain Wars: Competitive interactions between SARS-CoV-2 strains are explained by Gibbs energy of antigen-receptor binding.
    Popovic M; Popovic M
    Microb Risk Anal; 2022 Aug; 21():100202. PubMed ID: 35155724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.